SBI Okasan Asset Management Co.Ltd. Makes New Investment in Genmab A/S Sponsored ADR $GMAB

SBI Okasan Asset Management Co.Ltd. bought a new position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 20,700 shares of the company’s stock, valued at approximately $673,000.

A number of other large investors have also added to or reduced their stakes in GMAB. Osaic Holdings Inc. grew its position in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the period. NewEdge Advisors LLC grew its position in Genmab A/S by 1,229.0% in the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after purchasing an additional 1,143 shares during the period. Brown Brothers Harriman & Co. grew its position in Genmab A/S by 143.4% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after purchasing an additional 780 shares during the period. Founders Capital Management grew its position in Genmab A/S by 40.0% in the 4th quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares during the period. Finally, EverSource Wealth Advisors LLC grew its position in Genmab A/S by 124.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock worth $44,000 after purchasing an additional 1,174 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Trading Down 2.6%

Shares of Genmab A/S stock opened at $26.33 on Friday. The company’s fifty day simple moving average is $27.01 and its 200-day simple moving average is $29.62. The stock has a market capitalization of $16.42 billion, a PE ratio of 19.95, a P/E/G ratio of 1.61 and a beta of 0.86. Genmab A/S Sponsored ADR has a 1-year low of $20.23 and a 1-year high of $35.43. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. BNP Paribas Exane upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 22nd. Truist Financial assumed coverage on shares of Genmab A/S in a research note on Wednesday. They set a “buy” rating and a $40.00 price target on the stock. Wall Street Zen cut shares of Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Morgan Stanley assumed coverage on shares of Genmab A/S in a research note on Monday, February 16th. They set an “equal weight” rating and a $34.00 price target on the stock. Finally, Guggenheim dropped their price target on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, February 23rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and an average price target of $37.93.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.